Title:
抗ＦＣイプシロン－Ｒ１アルファ（ＦＣＥＲ１Ａ）抗体、ＦＣＥＲ１ＡおよびＣＤ３に結合する二重特異性抗原結合分子、ならびにそれらの使用
Document Type and Number:
Japanese Patent JP7402223
Kind Code:
B2
Abstract:
The present invention provides novel full-length human antibodies that bind to human Fc epsilon-R1 alpha (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both Fc epsilon-R1 alpha and CD3 and activate T cells via the CD3 complex in the presence of Fc epsilon-R1 alpha-expressing cells. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced Fc epsilon-R1 alpha-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of allergies, including anaphylaxis.
Inventors:
Orengo, Jamie M.
Rimnander, Andre
Kim, The H.
Murphy, Andrew Jay.
Rimnander, Andre
Kim, The H.
Murphy, Andrew Jay.
Application Number:
JP2021510030A
Publication Date:
December 20, 2023
Filing Date:
August 22, 2019
Export Citation:
Assignee:
REGENERON PHARMACEUTICALS, INC.
International Classes:
C12N15/13; A61K38/02; A61K39/395; A61P11/06; A61P17/04; A61P37/08; A61P43/00; C07K16/28; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/62; C12N15/63; C12P21/08
Domestic Patent References:
| JP2008515780A |
Foreign References:
| WO2017180913A2 | ||||
| WO2018067331A1 |
Other References:
THE JOURNAL OF BIOLOGICAL CHEMISTRY,2010年,Vol.285, No.27,pp.20850-20859
Attorney, Agent or Firm:
Shusaku Yamamoto
Natsuki Morishita
Natsuki Morishita